Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial
Gluz, O., Nitz, U. A., Harbeck, N., Ting, E., Kates, R., Herr, A., Lindemann, W., Jackisch, C., Berdel, W. E., Kirchner, H., Metzner, B., Werner, F., Schütt, G., Frick, M., Poremba, C., Diallo-Danebrock, R., Mohrmann, S.
Published in Annals of oncology (01.05.2008)
Published in Annals of oncology (01.05.2008)
Get full text
Journal Article
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12 weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Nitz, U A, Gluz, O, Christgen, M, Grischke, E-M, Augustin, D, Kuemmel, S, Braun, M, Potenberg, J, Kohls, A, Krauss, K, Stefek, A, Schumacher, C, Forstbauer, H, Reimer, T, Fischer, H, Liedtke, C, Wuerstlein, R, Schumacher, J, Kates, R, Kreipe, H, Harbeck, N
Published in Annals of oncology (01.11.2017)
Published in Annals of oncology (01.11.2017)
Get full text
Journal Article
Corrigendum to “De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel”: [Annals of Oncology 28 (2017) 2768-2772]
Nitz, U.A., Gluz, O., Christgen, M., Grischke, E.-M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N.
Published in Annals of oncology (01.03.2022)
Published in Annals of oncology (01.03.2022)
Get full text
Journal Article
De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR− phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertuzumab ± weekly paclitaxel
Nitz, U.A., Gluz, O., Christgen, M., Grischke, E. -M., Augustin, D., Kuemmel, S., Braun, M., Potenberg, J., Kohls, A., Krauss, K., Stefek, A., Schumacher, C., Forstbauer, H., Reimer, T., Fischer, H., Liedtke, C., Wuerstlein, R., Schumacher, J., Kates, R., Kreipe, H., Harbeck, N.
Published in Annals of oncology (01.11.2017)
Published in Annals of oncology (01.11.2017)
Get full text
Journal Article
Response
Moebus, V., Jackisch, C., Schneeweiss, A., Huober, J., Lueck, H.-J., du Bois, A., Thomssen, C., Kurbacher, C., Kuhn, W., Nitz, U. A., Runnebaum, I. B., Hinke, A., Kreienberg, R., Untch, M.
Published in JNCI : Journal of the National Cancer Institute (26.03.2014)
Published in JNCI : Journal of the National Cancer Institute (26.03.2014)
Get full text
Journal Article
Abstract P1-09-05: The role of immune and apoptosis markers for prediction of pCR in the WSG-ADAPT HER2+/HR+ phase II trial evaluating 12-weeks of neoadjuvant TDM1 ± endocrine therapy (ET) versus T + ET in HER2-positive hormone-receptor-positive early breast cancer (EBC)
Harbeck, N, Nitz, UA, Matthias, C, Kates, R, Braun, M, Kümmel, S, Schumacher, C, Potenberg, J, Kraemer, S, Kleine-Tebbe, A, Augustin, D, Aktas, B, Forstbauer, H, Tio, J, Liedtke, C, Grischke, E-M, de Haas, SL, Deurloo, R, Schumacher, J, Wuerstlein, R, Kreipe, HH, Gluz, O
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Published in Cancer research (Chicago, Ill.) (15.02.2017)
Get full text
Journal Article
Retrospective analysis of WSG AM01 tandem high dose chemotherapy trial in high risk primary breast cancer: A hypothesis generating study
Nitz, U. A., Gluz, O., Herr, A., Ting, E., Mohrmann, S., Frick, M., Jackisch, C., Poremba, C., Lindemann, W., Diallo-Danebrock, R.
Published in Journal of clinical oncology (20.06.2006)
Published in Journal of clinical oncology (20.06.2006)
Get full text
Journal Article
Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial
Nitz, Ulrike Anneliese, Mohrmann, Svjetlana, Fischer, Johannes, Lindemann, Walter, Berdel, Wolfgang E, Jackisch, Christian, Werner, Christoph, Ziske, Carsten, Kirchner, Hartmut, Metzner, Bernd, Souchon, Rainer, Ruffert, Ute, Schütt, Gerhart, Pollmanns, Anke, Schmoll, Hans Joachim, Middecke, Constantin, Baltzer, Jörg, Schrader, Iris, Wiebringhaus, Herrmann, Ko, Yon, Rösel, Siegfried, Schwenzer, Thomas, Wernet, Peter, Hinke, Axel, Bender, Hans Georg, Frick, Markus
Published in The Lancet (British edition) (03.12.2005)
Published in The Lancet (British edition) (03.12.2005)
Get full text
Journal Article
Single versus tandem high dose chemotherapy (HDC) with hematopoietic stem cell support in patients with chemosensitive metastatic breast cancer (BC) –results from a multicenter phase III trial
Nitz, U. A., Kroeger, N., Frick, M., Mohrmann, S., Metzner, B., Ko, Y., Berdel, E., Ziske, C., Bender, H. G., Zander, A.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article
Single versus tandem high dose chemotherapy (HDC) with hematopoietic stem cell support in patients with chemosensitive metastatic breast cancer (BC) –results from a multicenter phase III trial
Nitz, U. A., Kroeger, N., Frick, M., Mohrmann, S., Metzner, B., Ko, Y., Berdel, E., Ziske, C., Bender, H. G., Zander, A.
Published in Journal of clinical oncology (15.07.2004)
Published in Journal of clinical oncology (15.07.2004)
Get full text
Journal Article